Quarterly report pursuant to Section 13 or 15(d)

Restricted Cash Equivalents and Investments (Schedule of Cash Equivalents and Available-for-Sale Securities) (Details)

v3.23.1
Restricted Cash Equivalents and Investments (Schedule of Cash Equivalents and Available-for-Sale Securities) (Details) - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost $ 3,707,759 $ 3,694,069
Gross Unrealized Losses (24,436) (48,841)
Fair Value 3,683,323 3,645,228
Cash Equivalents 1,665,266 978,462
Short-Term Investments 2,018,057 2,666,766
Cash and Cash Equivalents [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 1,665,266 978,462
Fair Value 1,665,266 978,462
Cash Equivalents 1,665,266 978,462
Money Market Funds [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 1,665,266 978,462
Fair Value 1,665,266 978,462
Cash Equivalents 1,665,266 978,462
Investments [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 2,042,493 2,715,607
Gross Unrealized Losses (24,436) (48,841)
Fair Value 2,018,057 2,666,766
Short-Term Investments 2,018,057 2,666,766
Corporate Notes/Bonds [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 2,042,493 2,715,607
Gross Unrealized Losses (24,436) (48,841)
Fair Value 2,018,057 2,666,766
Short-Term Investments $ 2,018,057 $ 2,666,766